{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-048090","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2024-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.892949+00:00","generated_at":"2026-05-29T12:49:29.992743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716","bullets":["Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.","Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.","Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.","Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.","Company remains development-stage; no FDA approvals for any product candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-048090","json":"https://secwatch.observer/filing/0001493152-24-048090.json","markdown":"https://secwatch.observer/filing/0001493152-24-048090.md","text":"https://secwatch.observer/filing/0001493152-24-048090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/0001493152-24-048090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:49:29.992743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}